Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
3.570
+0.490 (15.91%)
At close: May 27, 2026, 4:00 PM EDT
3.610
+0.040 (1.12%)
After-hours: May 27, 2026, 7:56 PM EDT
Editas Medicine Stock Forecast
Stock Price Forecast
According to 13 analysts polled by S&P Global, Editas Medicine stock has a consensus rating of "Buy" and an average price target of $5.78. The average 1-year stock price forecast is 61.90% higher than the current stock price, while the lowest is $1.00 (-71.99%) and the highest is $15 (+320.17%).
Price Target: $5.78 (+61.90%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Editas Medicine stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 7 | 7 | 7 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 7 | 6 | 6 | 5 | 5 | 4 |
| Sell | 2 | 2 | 2 | 2 | 2 | 2 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 14 | 14 | 14 | 14 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI | Evercore ISI | Buy Maintains $15 | Buy | Maintains | $15 | +320.17% | May 27, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $5 | Buy | Reiterates | $5 | +40.06% | May 26, 2026 |
| JonesTrading | JonesTrading | Buy Maintains $13 → $8 | Buy | Maintains | $13 → $8 | +124.09% | May 14, 2026 |
| Bank of America Securities | Bank of America Securities | Sell Maintains n/a | Sell | Maintains | n/a | n/a | May 7, 2026 |
| RBC Capital | RBC Capital | Hold Maintains $4 | Hold | Maintains | $4 | +12.04% | May 6, 2026 |
Financial Forecast
Revenue This Year
24.01M
from 40.52M
Decreased by -40.76%
Revenue Next Year
14.33M
from 24.01M
Decreased by -40.31%
EPS This Year
-0.99
from -1.80
EPS Next Year
-0.94
from -0.99
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 104.0M | 34.0M | ||||||
| Avg | 24.0M | 14.3M | ||||||
| Low | 5.7M | 2.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 156.5% | 41.8% | ||||||
| Avg | -40.8% | -40.3% | ||||||
| Low | -85.9% | -91.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.42 | -0.30 | ||||||
| Avg | -0.99 | -0.94 | ||||||
| Low | -1.16 | -1.09 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.